Head-To-Head Contrast: Evaxion Biotech A/S (NASDAQ:EVAX) versus SOPHiA GENETICS (NASDAQ:SOPH)

Evaxion Biotech A/S (NASDAQ:EVAX) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Earnings and Valuation

This table compares Evaxion Biotech A/S and SOPHiA GENETICS’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$70,000.00	243.45	-$22.12 million	($4.33)	-0.73
SOPHiA GENETICS	$62.37 million	4.88	-$78.98 million	($1.12)	-4.16

Evaxion Biotech A/S has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Evaxion Biotech A/S and SOPHiA GENETICS, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
SOPHiA GENETICS	0	0	3	0	3.00

Evaxion Biotech A/S currently has a consensus price target of $11.00, indicating a potential upside of 249.21%. SOPHiA GENETICS has a consensus price target of $7.33, indicating a potential upside of 57.37%. Given Evaxion Biotech A/S’s higher possible upside, equities analysts clearly believe Evaxion Biotech A/S is more favorable than SOPHiA GENETICS.

Profitability

This table compares Evaxion Biotech A/S and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	N/A	N/A	-99.11%
SOPHiA GENETICS	-113.71%	-47.56%	-35.80%

Volatility & Risk

Evaxion Biotech A/S has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Insider and Institutional Ownership

11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Evaxion Biotech A/S beats SOPHiA GENETICS on 7 of the 13 factors compared between the two stocks.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.